Multivariable analyses for clinical outcome in the validation set of younger adult patients with CN-AML
| Variable in final model . | DFS . | OS . | EFS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| circKLHL8, high vs low* | 0.53 (0.30-0.91) | .02 | 0.53 (0.32-0.88) | .01 | 0.46 (0.28-0.76) | .002 |
| circFCHO2, high vs low* | — | — | 0.45 (0.27-0.75) | .002 | 0.56 (0.34-0.92) | .02 |
| FLT3-ITD, present vs absent | 2.53 (1.46-4.39) | <.001 | — | — | — | — |
| DNMT3A, mutated vs wild type | — | — | — | — | 1.93 (1.18-3.16) | .009 |
| MN1, high vs low* | 2.23 (1.31-3.80) | .003 | 2.63 (1.59-4.36) | <.001 | 2.15 (1.30-3.56) | .003 |
| Variable in final model . | DFS . | OS . | EFS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| circKLHL8, high vs low* | 0.53 (0.30-0.91) | .02 | 0.53 (0.32-0.88) | .01 | 0.46 (0.28-0.76) | .002 |
| circFCHO2, high vs low* | — | — | 0.45 (0.27-0.75) | .002 | 0.56 (0.34-0.92) | .02 |
| FLT3-ITD, present vs absent | 2.53 (1.46-4.39) | <.001 | — | — | — | — |
| DNMT3A, mutated vs wild type | — | — | — | — | 1.93 (1.18-3.16) | .009 |
| MN1, high vs low* | 2.23 (1.31-3.80) | .003 | 2.63 (1.59-4.36) | <.001 | 2.15 (1.30-3.56) | .003 |
Variables considered for model inclusion were: circKLHL8 (high vs low), circFCHO2 (high vs low), circCFLAR (high vs low), circSMC1A (high vs low), age (as a continuous variable, in 10-y increments), sex (male vs female), race (white vs nonwhite), white blood cell count (as a continuous variable, in 50-unit increments), hemoglobin (as a continuous variable, in 1-unit increments), platelet count (as a continuous variable, in 50-unit increments), extramedullary involvement (present vs absent), ASXL1 mutations (mutated vs wild type), CEBPA mutations (double mutated vs single mutated or wild type), DNMT3A mutations (mutated vs wild type), FLT3-ITD (present vs absent), FLT3-TKD (present vs absent), IDH1 mutations (mutated vs wild type), IDH2 mutations (mutated vs wild type), NPM1 mutations (mutated vs wild type), RUNX1 mutations (mutated vs wild type), SF1 (mutated vs wild type), SF3A1 (mutated vs wild type), SF3B1 (mutated vs wild type), SRSF2 (mutated vs wild type), TET2 mutations (mutated vs wild type), U2AF1 (mutated vs wild type), U2AF2 (mutated vs wild type), WT1 mutations (mutated vs wild type), ZRSR2 (mutated vs wild type), ERG expression levels (high vs low), BAALC expression levels (high vs low), MN1 expression levels (high vs low), miR-181a expression levels (high vs low), miR-3151 (expressed vs not expressed), and miR-155 expression levels (high vs low).
CI, confidence interval.
*The median expression value was used as the cut point.